These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 31392195)

  • 41. Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk.
    Van den Hout JM; Kamphoven JH; Winkel LP; Arts WF; De Klerk JB; Loonen MC; Vulto AG; Cromme-Dijkhuis A; Weisglas-Kuperus N; Hop W; Van Hirtum H; Van Diggelen OP; Boer M; Kroos MA; Van Doorn PA; Van der Voort E; Sibbles B; Van Corven EJ; Brakenhoff JP; Van Hove J; Smeitink JA; de Jong G; Reuser AJ; Van der Ploeg AT
    Pediatrics; 2004 May; 113(5):e448-57. PubMed ID: 15121988
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapeutic Options for the Management of Pompe Disease: Current Challenges and Clinical Evidence in Therapeutics and Clinical Risk Management.
    Bolano-Diaz C; Diaz-Manera J
    Ther Clin Risk Manag; 2022; 18():1099-1115. PubMed ID: 36536827
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Alglucosidase alfa enzyme replacement therapy as a therapeutic approach for a patient presenting with a PRKAG2 mutation.
    Austin SL; Chiou A; Sun B; Case LE; Govendrageloo K; Hansen P; Kishnani PS
    Mol Genet Metab; 2017; 120(1-2):96-100. PubMed ID: 27692944
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term outcomes of very early treated infantile-onset Pompe disease with short-term steroid premedication: experiences from a nationwide newborn screening programme.
    Yang CF; Liao TE; Chu YL; Chen LZ; Huang LY; Yang TF; Ho HC; Kao SM; Niu DM
    J Med Genet; 2023 May; 60(5):430-439. PubMed ID: 36137614
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review.
    Desai AK; Li C; Rosenberg AS; Kishnani PS
    Ann Transl Med; 2019 Jul; 7(13):285. PubMed ID: 31392197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. L-alanine supplementation in Pompe disease (IOPD): a potential therapeutic implementation for patients on ERT? A case report.
    Rovelli V; Zuvadelli J; Piotto M; Scopari A; Dionigi AR; Ercoli V; Paci S; Cefalo G; Salvatici E; Banderali G
    Ital J Pediatr; 2022 Mar; 48(1):48. PubMed ID: 35346323
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Individualized Assessment of Exercise Capacity in Response to Acute and Long-Term Enzyme Replacement Therapy in Pediatric Pompe Disease.
    Bar-Yoseph R; Tal G; Dumin E; Hanna M; Mainzer G; Zucker-Toledano M; Shallufi G; Jahshan M; Mandel H; Bentur L
    J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834457
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pompe disease in Austria: clinical, genetic and epidemiological aspects.
    Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV
    J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
    Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
    Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Very Early Treatment for Infantile-Onset Pompe Disease Contributes to Better Outcomes.
    Yang CF; Yang CC; Liao HC; Huang LY; Chiang CC; Ho HC; Lai CJ; Chu TH; Yang TF; Hsu TR; Soong WJ; Niu DM
    J Pediatr; 2016 Feb; 169():174-80.e1. PubMed ID: 26685070
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Airway abnormalities in very early treated infantile-onset Pompe disease: A large-scale survey by flexible bronchoscopy.
    Yang CF; Niu DM; Tai SK; Wang TH; Su HT; Huang LY; Soong WJ
    Am J Med Genet A; 2020 Apr; 182(4):721-729. PubMed ID: 31953985
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [A new phenotype of infantile-onset Pompe disease].
    Nascimento A; Villalobos-Pinto E
    Rev Neurol; 2018 Feb; 66(4):121-124. PubMed ID: 29435968
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Clinical Management of Pompe Disease: A Pediatric Perspective.
    Marques JS
    Children (Basel); 2022 Sep; 9(9):. PubMed ID: 36138713
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Muscle imaging data in late-onset Pompe disease reveal a correlation between the pre-existing degree of lipomatous muscle alterations and the efficacy of long-term enzyme replacement therapy.
    Gruhn KM; Heyer CM; Güttsches AK; Rehmann R; Nicolas V; Schmidt-Wilcke T; Tegenthoff M; Vorgerd M; Kley RA
    Mol Genet Metab Rep; 2015 Jun; 3():58-64. PubMed ID: 26937398
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness analysis of enzyme replacement therapy (ERT) for treatment of infantile-onset Pompe disease (IOPD) in the Iranian pharmaceutical market.
    Hashempour R; Davari M; Pourreza A; Alaei M; Ahmadi B
    Intractable Rare Dis Res; 2020 Aug; 9(3):130-136. PubMed ID: 32844068
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
    Kishnani PS; Beckemeyer AA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease.
    Nilsson MI; Kroos MA; Reuser AJ; Hatcher E; Akhtar M; McCready ME; Tarnopolsky MA
    Gene; 2014 Mar; 537(1):41-5. PubMed ID: 24384324
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cardiac response to enzyme replacement therapy in infantile Pompe disease with severe hypertrophic cardiomyopathy.
    Avula S; Nguyen TM; Marble M; Lilje C
    Echocardiography; 2017 Apr; 34(4):621-624. PubMed ID: 28266734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Infantile-onset Pompe disease with neutropenia: Treatment decisions in the face of a unique phenotype.
    Riedy M; Zhang JF; Huang T; Swayampakula AK
    JIMD Rep; 2023 Jan; 64(1):17-22. PubMed ID: 36636589
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Clinical sequelae of 17 cases with glycogen storage disease type II/Pompe disease].
    Zhang HB; Zhang WM; Qiu JJ; Meng Y; Qiu ZQ
    Zhonghua Er Ke Za Zhi; 2012 Jun; 50(6):415-9. PubMed ID: 22931935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.